Increased Anti-Mullerian Hormone in polycystic ovary syndrome, may be due to overactive follicles rather than reflect antral follicle count.
Does Anti-Mullerian Hormone reflect antral follicle count similarly in women with or without polycystic ovary syndrome or polycystic ovarian morphology?
Women who delivered preterm in 1999–2006. For each index woman, a woman with a term delivery was identified.
Participation rate was 69%. Between 2006–2008, 262 women were included, and diagnosed to have polycystic ovary syndrome, polycystic ovarian morphology or to be normal controls.
Blood tests, a clinical examination and vaginal ultrasound.
Main Outcome Measure(s)
Anti-Mullerian Hormone / antral follicle count -ratio, SHBG, androstenedione and insulin, to test potential influence on the Anti-Mullerian Hormone / antral follicle count -ratio.
Mean Anti-Mullerian Hormone / antral follicle count ratio in women with polycystic ovary syndrome or polycystic ovarian morphology was similar to that of the controls (polycystic ovary syndrome: 1,2 p = 0,10 polycystic ovarian morphology: 1,2, p = 0,27 Controls 1,3). Anti-Mullerian Hormone showed a positive linear correlation to antral follicle count in all groups. Multivariate analysis did not change the results.
We confirmed the positive correlation between AMH and follicle count. Anti-Mullerian Hormone seems to be a reliable predictor of antral follicle count, independent of polycystic ovary syndrome diagnosis or ovarian morphology.
Citation: Christiansen SC, Eilertsen TB, Vanky E, Carlsen SM (2016) Does AMH Reflect Follicle Number Similarly in Women with and without PCOS? PLoS ONE 11(1): e0146739. doi:10.1371/journal.pone.0146739
Editor: Wan-Xi Yang, Zhejiang University, CHINA
Received: August 18, 2015; Accepted: December 20, 2015; Published: January 22, 2016
Copyright: © 2016 Christiansen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The study was funded by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU) (TBE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Anti-Mullerian Hormone (AMH) is produced by the granulosa cells in the premature ovarian follicle. The level of AMH is relatively constant during the menstrual cycle as neither the primordial follicles, the dominant follicle nor corpus luteum secrete AMH [1–4]. During the menstrual cycle, the intra-individual variation in AMH may be up to 13% in infertile women with a regular cycle . The intra-follicular concentration of AMH depends on the follicle size . As AMH is mainly produced by the small antral follicles, it can be used as a proxy for the remnant follicle pool . AMH peaks when women are in their early twenties . Later in life, AMH decreases until menopause. In menopause it is no longer detectable .
Contrary to the normal physiological condition, where primordial follicles follow a continuous development, women with polycystic ovary syndrome (PCOS) have their ovarian follicles arrested in the pre-antral and antral stages . At least two out of three criteria have to be fulfilled to meet the Rotterdam 2003 criteria for PCOS; oligo- or anovulation (OA), clinical and/or biochemical signs of hyperandrogenism (HA), and the presence of polycystic ovaries defined as at least 12 pre-antral follicles, 2–9 mm in diameter and/or increased ovarian volume >10 ml in at least one ovary (AFC) [11–14]. The cut-off at 9 mm seems crucial, as in vitro studies show that AMH-levels are low or undetectable in larger follicles .
Recently AMH-levels were shown to reflect polycystic ovarian morphology (PCOM), to a high extent. Although AMH cut-off levels of 10–20 pmol/l identifies PCOM (AFC ≥ 12) with a high sensitivity (resp. 98.8 and 91.6%), the corresponding specificities were poor (resp. 39.8 and 69.8%) . A recent study found asymptomatic women with PCOM to have increased levels of AMH compared to asymptomatic women with normal ovaries . When combined with other PCOS- criteria, the sensitivity and specificity in distinguishing women with PCOS from women with ovulatory cycles without HA, increases to 92% and 97%, respectively [18–19].
Even in follicles of similar size, in vitro ovarian cell cultures from women with PCOS show substantially higher levels of AMH as compared to women with normal cycles .
AMH-excess might in part be explained by increased AMH synthesis per follicle in PCOS-women, rather than reflecting the increased number of follicles arrested in the pre-antral and antral stages. Importantly, AMH is essential in limiting the further growth of pre-antral and antral follicles, possibly by inhibition of the effect of follicle stimulating hormone (FSH) . There may be a subgroup of PCOS-women where follicles exceed the average production, as a recent study found the AMH/AFC ratio to be significantly increased in 87 PCOS women when compared to controls, while the AMH/AFC ratio in 131 PCOM-women was comparable to that of the control-group .
In the present study we aimed to analyze the relation between AMH and AFC in women with PCOS and PCOM and in women without these features, i.e. normal controls. To do so, we used data from a previously published case-control study .
The present study comprised 262 women from a former case-control study . In the original study women from a well-defined hospital catchment area (Namsos hospital, Norway) consisting of 17 municipalities in Nord-Trøndelag County were included. Women who had experienced a preterm birth were compared to women with a term birth after an uncomplicated pregnancy. Two-hundred and eighty-three out of 410 invited women responded, leading to a response rate of 69%. Twenty-one women were subsequently excluded because of a language barrier, or pregnancy/breast feeding at the time of inclusion. During former published results on preterm deliveries, women with twin deliveries in the index pregnancy were excluded (n = 21), but were included in the current study. In all, 133 of the 262 included women had a history of preterm birth. Clinical examination and blood drawing were performed between October 2006 and April 2008. S1 Fig shows the design of the former study, which was the basis of the current study.
Oligo-anovulation (OA) was defined as self-reported menstrual cycle length of ≥ 35 days or < 10 menstrual periods per year. Clinical hyperandrogenism (HA) was defined as a FG score ≥ 8 . Biochemical HA was defined as serum testosterone > 2.5 nmol/l, free testosterone index (FTI) ≥ 0.6 and/or androstenedione (A4) ≥ 10.0 nmol/l.
PCOM was defined as ≥ 12 pre-antral follicles measuring 2–9 mm in diameter, and/or increased ovarian volume (>10 ml) in at least one ovary. PCOS was defined according to the Rotterdam criteria . Based on the above mentioned criteria the study population was classified as PCOS (n = 56), PCOM (n = 58) and controls (n = 148). The phenotypic characteristics of the PCOS women were as follows: HA + PCOM (n = 27), HA + OA + PCOM (n = 16), OA + PCOM (n = 12) and HA + OA (n = 1). Accordingly, only one woman with PCOS did not have PCOM, and was reported among the 149 women without PCOM in the former publication . Among the 148 controls, 16 had isolated HA and three had OA. All the 58 PCOM women were eumenorrhoic and normo-androgenic.
Seven women with missing AFC in either the left or the right ovary were censored in the subsequent analyses of AFC and AMH / AFC-ratio. Six women with AFC ranging from 4 to 17 belonging to the control group were included in the subsequent analyses, despite having their AMH-value measured to be zero.
The Study was approved by the Regional Committee for Research Ethics in Health Region IV in Norway. An informed consent form was signed by all women before inclusion in the study. The study was carried out according to the Helsinki Declaration.
Measurement of Antral Follicles
The gynecological examination was performed with US equipment General Electric Logiq Book XP with vaginal probe 7,5 MHz (General Electric Medical Systems, Solingen, Germany). Ovary size was measured in three dimensions, and the volume was subsequently calculated by the formula: height × width × depth × 0.5. All visible follicles of 2–9 mm in diameter in both ovaries were included in the AFC. All ultrasound examinations were performed by the same investigator (TBE).
Blood samples were drawn from an antecubital vein between 08 and 11 am after an overnight fast, centrifuged at room temperature within 30 minutes and stored at -70°C until analysis.
Although the intention was that the blood draw and clinical examination should be performed within the first 5 days of the menstrual cycle this aim was only achieved in 32 participants. S2 Fig shows the distribution of women with PCOS, PCOM and controls among quartiles of years in between the blood draw and the analysis of insulin, androgens and AMH.
For the AMH analysis, an enzymatically amplified two-site immunoassay (ACTIVE®MIS/AMH enzyme-linked immunosorbent assay (ELISA)) was used. Reagents and calibrators for the AMH analysis were supplied by the manufacturer (Diagnostic Systems Laboratories, Inc, Webster, TX, USA). For the A4 analysis, a competitive immunoassay using antibody-coated tubes was used (Coat-A-Count®). Reagents and calibrators for the A4 analysis was supplied by the manufacturer (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA), whereas ethyl ether was the organic solvent extraction used prior to quantification. For the testosterone analysis, an enzyme immunoassay for the quantitative determination in serum (ELISA) was used. Reagents and calibrators for the testosterone analysis was supplied by the manufacturer (DRG Instruments GmbH, Marburg, Germany), whereas dichloromethane was the organic solvent extraction used prior to quantification. Sex hormone binding globulin (SHBG) and insulin were measured quantitatively in serum using an ELISA method, with reagents and calibrators from the manufacturer (DRG Instruments GmbH, Marburg, Germany) . FTI was calculated according to the formula; testosterone×10/SHBG.
All measurements were performed in singles, and all analyses were performed on kits from the same batch. Intra- and inter-assay coefficients of variation were 4.2% and 7.7% for AMH, 5.6% and 2.2% for A4, 9.5% and 14.0% for testosterone, 6.6% and 5.5% for SHBG and 3.6% and 4.9% for insulin.
All statistical procedures were performed using the PASW version 20 (IBM, SPSS, Armonk, NY, USA). Means and standard deviations (SD) were calculated, and the differences between the study groups were compared with two-tailed Mann-Whitney U tests for independent samples or Pearson’s chi-square test. Significance was set as a p-value < 0.05.
Univariate and multivariable linear regression analyses were used to study variables possibly associated to AMH. Variables with a p-value ≤ 0.1 in univariate analyses in at least one study group were included in the multivariable analyses.
Women with PCOS and PCOM were significantly younger than controls, while body mass index (BMI) was comparable in the three groups (Table 1). A4 tended to be higher in PCOS women compared to PCOM women (p = 0.02), while in PCOM it was higher than in controls (p< 0.01). The FTI in PCOS-women was twice of that in PCOM-women and controls (p< 0.01). Insulin levels were increased in PCOS-women as compared to the control group. In PCOM-women, the mean insulin-level was similar to the control group.
Analyzing data on AMH and AFC separately for women aged above or below the median age of 35 years, confirmed that AMH and AFC are increased in women with PCOS or PCOM as compared to control women (S1–S3 Tables).
The younger group (≥ 20 and ≤ 35 years of age) had higher mean AMH and AFC as compared to the elder group (> 35 years of age), and this pattern was seen in women with PCOS, PCOM and in controls, with the exception of mean AMH in PCOM-women, which was not different in the younger vs the elder group (S1–S3 Tables).
The AFC in women with PCOS was 3-fold increased, and in PCOM-women 2-fold increased compared to controls (p< 0.01). Also AMH was 3- and 2-fold increased in women with PCOS and PCOM compared to controls, resulting in comparable AMH/AFC-ratios; 1.2, 1.2 and 1.3 in PCOS, PCOM and controls (Table 1, Fig 1).
* Censored and not shown 2 extreme values of AMH/AFC-ratio, which belonged to 2 control women, respectively 13.30 and 7.58, stipled line: 95% Confidence interval of the regression line.
Predictors of AMH
In univariate regression analyses, AMH decreased with age in all three study groups. A4 was positively correlated to AMH in PCOM only (Table 2). BMI, FTI and insulin levels showed no correlations to AMH in any of the three study groups. High AFC was strongly correlated to high AMH in all three study groups (PCOS: r = 0.77, PCOM: r = 0.70, normal controls: r = 0.42). The linear relationship between age and AMH/AFC-ratio is shown in Fig 2 (β: -0.04, CI95: -0.06; -0.01). This β expresses the lowering in AMH/AFC-ratio for each unit of rise in age. The linear relationships between AFC and AMH were as follows in the three study groups: PCOS: β: 1.42, CI95: 1.09; 1.74, PCOM: β: 2.04, CI95: 1.47; 2.61, normal controls: β: 0.99, CI95: 0.64; 1.35). These βs express the rise in AMH for each unit of rise in AFC.
AFC remained positively correlated to AMH in all three groups also when we adjusted for age, BMI and A4. Age remained negatively correlated to AMH in control women only.
The tendency of a negative correlation between BMI and AMH was significant in PCOS-women. In normal control women, BMI tended to be positively correlated to AMH, although not reaching statistical significance.
Hormonal Contraceptive Use
Twenty-one percent of the PCOS-women, 36% of the PCOM-women and 39% of the control women reported that they used hormonal contraceptives at the blood draw. Excluding women on hormonal contraception from the analyses, did not alter the results, i.e. the AMH/AFC-ratio remained similar in women with PCOS, PCOM and the controls.
Among those 90 patients who reported the use of hormonal contraception, 25 reported the use of oral hormonal contraception, and one woman reported the use of dermal contraception with progestin and estrogen. The distribution of the use of hormonal contraception among women with PCOS, PCOM and controls is reported in S4 Table.
Only 2 out of the 25 women who reported to use of oral contraception, did mention the brand of the oral contraception, and in both cases it was a progestin-only with a 3rd generation gestagene.
Blood Pressure, Impaired Glucosetolerance, and Smoking Status
There was no difference in neither systolic nor diastolic blood pressure (mean of last 2 of 3 measurements) when we compared the groups of PCOS, PCOM to the control group (S5 Table).
The prevalence of diabetes was 1.8% in the PCOS-group, 8.6% in the PCOM-group, and 1.4% in the control group (S6 Table).
The prevalence of impaired glucose tolerance was 21.4% in the PCOS-group, 15.5% in the PCOM-group, and 18.2% in the control group (S6 Table).
The prevalences of smoking at the blood draw among the 3 groups were as followed: PCOS: 21.4%, PCOM: 19.0%, Controls: 21.6% (Data not shown).
The most important finding of this study is the close and similar relationship between serum AMH and AFC in PCOS, PCOM and normal control women. This supports the view that increased serum AMH levels in PCOS are results of a higher number of antral follicles and not increased synthesis of AMH per follicle. Importantly, this relationship between AMH and AFC was unaffected by whether or not the women used hormonal contraception.
Some studies report higher intra-follicular levels of AMH in PCOS women compared to controls, indicating that AMH-excess could result from overactive follicles [15, 24]. However, high intra-follicular levels of AMH do not necessarily imply increased release of AMH from the follicles.
Intra-follicular AMH levels were found to be 75-fold higher in anovulatory PCOS-women compared to women with normal ovary morphology, when follicles were size matched. Intra-follicular AMH decreased with increasing follicle-size . Although this indicates that follicles of women with PCOM synthetize more AMH than those of women with normal ovary morphology, this was a highly selected, small group with unmatched controls . The circulating AMH levels were not reported.
In PCOS-women referred to routine laparoscopy or laparotomy, intra-follicular AMH-levels were 60-fold higher than serum AMH-levels . Intra-follicular AMH levels in anovulatory PCOS women were 6-fold higher than in eumenorrhoic women. Serum levels of AMH was highly correlated to the intra-follicular levels in PCOS-women (r = 0.86), in contrast to eumennorhoic controls .
Our results are partly in line with a former study (n = 104) which found a correlation of serum-AMH to follicle count when follicles were 2–5 mm but not in follicles 6–9 mm . The AMH/AFC-ratios were found to be similar in women with (n = 59) or without (n = 45) PCOS .
A larger study on 366 healthy eumenorroic women, aged 20–41 years reported a stronger correlation (r = 0.86) between AMH and AFC than we found in our control group, but underestimation of AMH was observed when AFC exceeded 20 follicles . AFC correlated positively to AMH if follicle size was < 8 mm, whereas it correlated negatively beyond that limit. This may explain why we found a somewhat weaker linear relation between AMH and AFC (2–9 mm). Although it has been shown that primordial follicles also contain AMH, most of the AMH-production originate from antral follicles sized 5–8 mm [27, 28].
Our results are contradicted by a recent study which found the median AMH/AFC-ratio to be significantly increased in 87 women with PCOS as compared to 131 women with PCOM and 218 normal controls . Similar to our study they defined PCOS according to the Rotterdam criteria and PCOM if an ovary had more than 12 follicles measuring 2–9 mm. Although they reported age as a median, their women with PCOS, PCOM and the controls, must have been approximately 2–4 year younger than our respective groups. The median AMH and AFC-count in our control group (11.2 and 12 respectively) are comparable to those of the control group of Bhide (11.95 and 12 respectively), despite that the blood test in Bhides study was not fixed to any day of the menstrual cycle, while our study aimed for a blood test within the first 5 days of the menstrual cycle (although only successful in a minority of the participants).
To explore if the difference in the two studies could be explained by the severity of PCOS, we performed an analysis restricting our PCOS-group to 16 PCOS-women with all three key features (HA, OA, PCOM) and still found the AMH/AFC ratio to be similar to that of controls (AMH/AFC-ratio PCOS = 1.1, p = 0.61). Nevertheless, the input of that study was totally different from ours, as their population was referred to a fertility clinic; our population was included with at least one pregnancy, which makes it probable that our population have lesser women with severe PCOS.
AMH decreased independently with age, in normal control women only . The absence of this relation in women with PCOS or PCOM, could represent the longevity of antral follicles with undiminished production of AMH.
Our results show that high BMI is correlated with lower AMH in PCOS-women. This is contrary to our expectations, as high BMI, high AMH-levels and high AFC are common findings in PCOS. Nevertheless, in multivariable analysis, BMI did not change the relation between AFC and AMH, indicating that the AMH/AFC-ratio is independent of BMI.
Strengths and Limitations of Our Study
In our study, women with PCOS and PCOM were significantly younger than the controls. We did not have the possibility to correct for antral follicles size distribution towards 2 mm or 9 mm. Our findings of a similar AMH/AFC-ratio between the groups can be explained if there is only a minor or no increase in serum-AMH when follicle-size increases from 2 to 9 mm. Alternatively, the relative distribution of follicle-size within the size range of 2–9 mm is similar between the three groups, whereas the AFC increases from controls towards PCOS-women.
In this study we did not do any measurements to exclude non-classical adrenal hyperplasia, which overall can be the cause of approximately 4% of the female patients with androgen excess . However, in Norway congenital adrenal hyperplasia is a relatively rare condition compared to other populations with another genetic background. Based on clinical experience approximately 1% of women referred for possible PCOS have other causes of hyperandrogenism.
We did not perform any imaging studies to exclude the possibility of androgen-producing tumors, which overall can account for approximately 0.2% of the cases of androgen excess 
In Norway, approximately 90% of women in the fertile age give birth, and the selection of participants to this study included consecutive participants who gave preterm birth, and the subsequent participant who gave birth at term. This selection implies that we have more women with preterm birth than we would expect from for instance a random sample from the background population. The consecutive inclusion of women who gave birth at term is believed to be more representative for the background population in the fertile age. Although the prevalence of PCOS was higher in the group who delivered preterm, there was no difference in mean age, AMH, AFC, or AMH/AFC-ratio among those who delivered preterm or at term (S7 Table) .
The “mix” of the term and the preterm group, implies a higher prevalence of PCOS than in the background population, as we did not include all term births in the period when we assembled the patients with preterm birth, but is an advantage in the current study, as this increased the power without increasing the study to compare the AMH/AFC-ratio in women with PCOS, to those without.
Our study is medium sized and fairly representative for women of fertile age. Several of the women diagnosed with PCOS or PCOM were not aware of their status before they entered the study. Among a random sample of women, AMH-levels seem to have a good correlation to follicle count in normal women as well as in women with PCOS or PCOM.
AMH seem to be a reliable predictor of AFC (2–9 mm), independent of PCOS diagnosis or ovarian morphology. Larger studies are needed to assess whether this is true for other populations and all subgroups of PCOS.
S1 Fig. Inclusion and exclusion decision tree for the current study.
S2 Fig. Period from blood draw to analysis, in quartiles of the passed period.
Black columns: Women with PCOS. Grey columns: Women with PCOM. White columns: Control women.
S1 Table. Young group 21–35 years (N = 140).
Difference compared to controls; Mann Whitney U test for independent samples.
S2 Table. Elder group 36–46 years (N = 122).
Difference compared to controls; Mann Whitney U test for independent samples.
Mann Whitney U test for independent samples.
S4 Table. Method of contraception in 90 women who used contraception with hormones.
S5 Table. Mean systolic and diastolic blood pressure, mean of last 2 of 3 measurements.
Difference compared to controls; Mann Whitney U test for independent samples.
S6 Table. The prevalence of diabetes, impaired glucose tolerance (IGT), and normal glucose tolerance (NGT) among women with PCOS, PCOM, and in controls.
S7 Table. Mean age, AMH, AFC, AMH/AFC-ratio, and prevalence PCOS among those who delivered preterm and at term.
Difference compared to controls; Mann Whitney U test for independent samples. Pearson’s chi-square test.
Conceived and designed the experiments: SMC TBE EV. Performed the experiments: TBE. Analyzed the data: SCC SMC EV TBE. Contributed reagents/materials/analysis tools: SCC SMC EV TBE. Wrote the paper: SCC SMC EV TBE.
- 1. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004 Feb;10(2):77–83. pmid:14742691 doi: 10.1093/molehr/gah015
- 2. Cook CL, Siow Y, Taylor S, Fallat ME. Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 2000 Apr;73(4):859–61. pmid:10731554 doi: 10.1016/s0015-0282(99)00639-1
- 3. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P et al. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004 Dec;19(12):2738–41. pmid:15459174 doi: 10.1093/humrep/deh508
- 4. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005 Apr;20(4):923–7. pmid:15640257 doi: 10.1093/humrep/deh688
- 5. van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010 Jan;25(1):221–7. doi: 10.1093/humrep/dep366. pmid:19840990
- 6. Andersen CY, Schmidt KT, Kristensen SG, Rosendahl M, Byskov AG, Ernst E. Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum Reprod 2010 May;25(5):1282–7. doi: 10.1093/humrep/deq019. pmid:20228388
- 7. Lutchman SK, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 2007 Jun 18;96(12):1808–16. pmid:17533402 doi: 10.1038/sj.bjc.6603814
- 8. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One 2011;6(7):e22024. doi: 10.1371/journal.pone.0022024. pmid:21789206
- 9. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002 Feb;77(2):357–62. pmid:11821097 doi: 10.1016/s0015-0282(01)02993-4
- 10. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014 May;20(3):370–85. doi: 10.1093/humupd/dmt062. pmid:24430863
- 11. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19–25. pmid:14711538 doi: 10.1093/humrep/deh098
- 12. Pache TD, Wladimiroff JW, Hop WC, Fauser BC. How to discriminate between normal and polycystic ovaries: transvaginal US study. Radiology 1992 May;183(2):421–3. pmid:1561343 doi: 10.1148/radiology.183.2.1561343
- 13. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003 Mar;18(3):598–603. pmid:12615832 doi: 10.1093/humrep/deg115
- 14. van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 1997 Mar;67(3):452–8. pmid:9091329 doi: 10.1016/s0015-0282(97)80068-4
- 15. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007 Jan;92(1):240–5. pmid:17062765 doi: 10.1210/jc.2006-1582
- 16. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012 Aug;27(8):2494–502. doi: 10.1093/humrep/des213. pmid:22693172
- 17. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antimullerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012 Jul;98(1):242–9. doi: 10.1016/j.fertnstert.2012.03.059. pmid:22541936
- 18. Fenton A, Panay N. Anti-Mullerian hormone—is it a clinically useful test? Climacteric 2013 Feb;16(1):1–2. doi: 10.3109/13697137.2013.756623. pmid:23320765
- 19. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011 Nov;26(11):3123–9. doi: 10.1093/humrep/der297. pmid:21926054
- 20. Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod 2014 Jun;29(6):1117–21. doi: 10.1093/humrep/deu076. pmid:24770999
- 21. Bhide P, Dilgil M, Gudi A, Shah A, Akwaa C, Homburg R. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimullerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. Fertil Steril 2015 Feb;103(2):537–41. doi: 10.1016/j.fertnstert.2014.10.033. pmid:25467043
- 22. Eilertsen TB, Vanky E, Carlsen SM. Increased prevalence of diabetes and polycystic ovary syndrome in women with a history of preterm birth: a case-control study. BJOG 2012 Feb;119(3):266–75. doi: 10.1111/j.1471-0528.2011.03206.x. pmid:22168920
- 23. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961 Nov;21:1440–7. pmid:13892577 doi: 10.1210/jcem-21-11-1440
- 24. Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008 Sep;23(9):2122–6. doi: 10.1093/humrep/den185. pmid:18550512
- 25. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003 Dec;88(12):5957–62. pmid:14671196 doi: 10.1210/jc.2003-030727
- 26. Bentzen JG, Forman JL, Johannsen TH, Pinborg A, Larsen EC, Andersen AN. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013 Apr;98(4):1602–11. doi: 10.1210/jc.2012-1829. pmid:23463653
- 27. Stubbs SA, Hardy K, Da Silva-Buttkus P, Stark J, Webber LJ, Flanagan AM et al. Anti-mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J Clin Endocrinol Metab 2005 Oct;90(10):5536–43. pmid:16030171 doi: 10.1210/jc.2005-0907
- 28. Jeppesen JV, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013 Aug;19(8):519–27. doi: 10.1093/molehr/gat024. pmid:23562944
- 29. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006 Jan;91(1):2–6. Epub 2005 Nov 1. pmid:16263820 doi: 10.1210/jc.2005-1457
- 30. Naver KV, Grinsted J, Larsen SO, Hedley PL, Jorgensen FS, Christiansen M et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. BJOG 2014 Apr;121(5):575–81. doi: 10.1111/1471-0528.12558. pmid:24418062